FDA approves new treatment for FOP
Total new heterotopic ossification volume decreased with treatment and increased with placebo at week 24.
-
By
-
Kathryn Wighton
-
September 28, 2026
-
Clinical Scorecard: FDA approves new treatment for FOP
At a Glance
| Category | Detail |
|---|
| Condition | Fibrodysplasia ossificans progressiva |
| Key Mechanisms | Mutation in activin A receptor-type 1 affecting bone growth regulation |
| Target Population | Adult and pediatric patients aged 12 years and older |
| Care Setting | Clinical trial and outpatient management |
Key Highlights
- Zilurgisertib (Atebrioz) approved to reduce heterotopic ossification volume
- Randomized, double-blind, placebo-controlled trial involved 63 patients
- Mean total new heterotopic ossification volume declined by 3.2 cm³ in treatment group
- Most common adverse effects include headache, joint pain, and nausea
- Effective contraception recommended for patients of reproductive potential
Guideline-Based Recommendations
Diagnosis
- Diagnosis based on clinical evaluation and imaging studies
Management
- Zilurgisertib administered orally at 100 mg once daily
Monitoring & Follow-up
- Monitor for adverse effects and efficacy through imaging
Risks
- Potential fetal harm; discontinue if pregnancy occurs
Patient & Prescribing Data
Patients with fibrodysplasia ossificans progressiva aged 12 years and older
Zilurgisertib may be taken with or without food
Clinical Best Practices
- Assess for contraindicated medications before prescribing zilurgisertib
- Provide counseling on the importance of effective contraception
Related Resources & Content
